A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)

Kim S, Kim S, Lee H

Drug Design, Development and Therapy 2020, 14:2831-2840

Published Date: 17 July 2020